A proton therapy systems provider has canceled its plans to go public and now plans to form a joint venture (JV) in China supported by a new investment agreement worth up to $200 million.

The medical device industry has enjoyed a rather healthy IPO window overall this year, but not all segments of the market have received a warm welcome from investors. Several genetic testing companies have gone public this year and while some of those firms had successful opening days, most have seen declining stock prices since trading began.

The market for weight loss devices has seen a flurry of recent activity, most recently with the FDA approval of an intragastric dual balloon system from Reshape Medical (San Clemente, Calif.).

Recently dubbed the sleeping giant on the M&A front because of its noticeable lack of deal activity in the first half of the year, Abbott (NYSE: ABT) (Abbott Park, Ill.) seemed to awaken from its hibernation on Thursday with an appetite for the massive transcatheter mitral valve replacement (TMVR) market.

A booming transcatheter aortic valve replacement/implant market knocked quarterly sales out of the park for Edwards Lifesciences (NYSE: EW) (Irvine, Calif.).

A significant cross-selling opportunity and a broader product offering are being cited as the strategic backbone of a $86 million cash-and-stock deal that will combine two device companies operating in the spine market.

For a company developing a technology intended to reduce noise, BioSig Technologies (OTCQB: BSGM) (Minneapolis) has been anything but quiet this year. The company is getting ready to seek FDA clearance for its Pure EP system, a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system.